DNCB sensitivity in cancer patients. A review based on sequential testing in 430 patients.
D000230:Adenocarcinoma / Q000276:immunology; D000328:Adult; D001943:Breast Neoplasms / Q000276:immunology / Q000473:pathology; D002294:Carcinoma, Squamous Cell / Q000276:immunology; D003110:Colonic Neoplasms / Q000276:immunology; D004137:Dinitrochlorobenzene; D005260:Female; D006801:Humans; D006968:Hypersensitivity, Delayed; D007111:Immunity, Cellular; D007153:Immunologic Deficiency Syndromes; D007156:Immunologic Memory; D008297:Male; D008545:Melanoma / Q000276:immunology; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local; D009369:Neoplasms / Q000276:immunology* / Q000473:pathology; D009578:Nitrobenzenes; D012509:Sarcoma / Q000276:immunology; D013274:Stomach Neoplasms / Q000276:immunology
D004137:Dinitrochlorobenzene; D009578:Nitrobenzenes